Immune Pharmaceuticals and Hadasit File a Joint Patent on the Oral Use of Anti-Eotaxin Monoclonal Antibodies, Including Bertilimumab, for the Treatment of GI and Liver Diseases
June 28, 2016
NEW YORK, June 7, 2016 /PRNewswire/ — Immune Pharmaceuticals Inc. (“Immune”), a biopharmaceutical company focused on the development of antibody-based therapeutics for the treatment of inflammatory diseases and cancer, and Hadasit, the Technology Transfer company of The Hadassah Medical Organization in Jerusalem, Israel, announced today that they together filed a provisional patent on the oral use…
Search
RECENT PRESS RELEASES
Related Post
